Member Profile
TRI Cap Portfolio - MGB Biopharma
First Investment April 2010
TRI Cap has joined in a funding round for MGB Biopharma Limited, a late preclinical stage biopharmaceutical company that is developing and commercialising a new class of antibacterial product: DNA Minor Groove Binders. Other parties to the funding were Archangel Informal Investments Ltd, Barwell plc and the Scottish Enterprise’s Scottish Co-investment Fund.
The technology has been licensed from the University of Strathclyde and has so far demonstrated very significant activity against Gram positive bacteria, including MRSA and also against some Gram negative bacteria. The technology involves a new class of DNA minor groove binders (MGBs), to be used as anti-bacterial drugs. These compounds have arisen from the work of a multidisciplinary team comprising medicinal chemists, molecular modellers and microbiologists.
September 2011
TRI Cap participates in a second funding round for MGB Biopharma, which secures £800,000 from existing investors TRI Cap, Archangel Informal Investment and the Scottish Co-investment Fund. The second tranche of funding is initiated in direct response to the company meeting the technology milestone of preclinical proof of concept for its lead compound MGB BP-3.
Read the news release here
Number of TRI Cap Investors: 17
TRI Cap Contact: John Hall
MGB Biopharma Contact: Dr Miroslav Ravic, CEO
183 St. Vincent Street
Glasgow
G2 5QD
E-mail: mravic@mgb-biopharma.com